Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced a definitive agreement for a registered direct offering expected to raise approximately $4 million in gross proceeds. The company will sell 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. In a concurrent private placement, Lantern will issue unregistered warrants to purchase up to 3,669,725 additional shares at the same exercise price, potentially generating another $4 million if fully exercised for cash. The offering is expected to close on or about September 30, 2026, subject to customary closing conditions, with Rodman & Renshaw LLC acting as exclusive placement agent. Lantern Pharma intends to use the net proceeds for working capital and other general corporate purposes.
This capital raise matters because it provides Lantern Pharma with financial runway to advance its proprietary RADR artificial intelligence and machine-learning platform, which is designed to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR aims to identify patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
The timing of the offering is significant as the biopharmaceutical industry increasingly adopts AI-driven approaches to drug discovery and development. Lantern's ability to secure funding at this juncture underscores investor confidence in its AI platform and its potential to bring more effective cancer treatments to market faster and at lower cost. The unregistered warrants will become exercisable subject to stockholder approval and will expire five years following that approval, giving the company a potential additional capital infusion if the stock price rises above the exercise price.
For investors and industry observers, the offering highlights the ongoing need for capital in clinical-stage biotech, even for companies with promising technology. The proceeds will support Lantern's operations as it continues to develop its pipeline and expand its AI capabilities. The news was distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions.
Lantern Pharma's news is available in its newsroom at https://ibn.fm/LTRN, and the full press release can be viewed at https://ibn.fm/PCJbt. As the company moves forward with this financing, the market will be watching to see how effectively it deploys the capital to achieve its mission of revolutionizing oncology drug development through artificial intelligence.
